BlossomHill Therapeutics, Inc. (BLSM) company profile
BLSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$15.13+1.48 (+10.84%)
Close on Nov 17, 2026Market cap $38.56MP/E –Yield –
About BlossomHill Therapeutics
Pharmaceutical Preparations, SIC 2834
BlossomHill Therapeutics, Inc. is listed on Nasdaq under the ticker BLSM, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- BlossomHill Therapeutics, Inc.
- Headquarters
- San Diego, CA
- Address
- 10255 Science Center Drive, Suite 200
- Phone
- (858) 732-3880
- Website
- bhtherapeutics.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- BLSM
- Exchange
- Nasdaq
- IPO date
- Aug 7, 2026
- Shares outstanding
- 32M, Sep 16, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1839970
- CUSIP
- 095130100
- ISIN
- US0951301003
- FIGI
- BBG00ZHSKKM1
- Share class FIGI
- BBG00ZHSKKN0
- EIN
- 85-1578711
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jingrong Jean Cui | President and CEO, Director | 3,973,138 |
| Yishan Li | Executive Chairman, Director | 3,859,703 |
| Vincent Paul Liptak | General Counsel | 134,099 |
| Jason A. Keyes | Chief Financial Officer | 700 |
| Geoffrey Raymond Oxnard | Chief Medical Officer | 17,785 |
| Advisors Llc Orbimed | Director | – |
| Capital GP VIII LLC OrbiMed | Director | 2,714,279 |
| Carl L. Gordon | Director | 2,714,279 |
| John P. Schmid | Director | 6,000 |
| Sundeep Agrawal | Director | 578,524 |
| Bihua Chen | Director | – |
| Sheila Gujrathi | Director | 90,160 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Aug 7, 2026
- Offer price
- $16.00
- Securities offered
- 9,375,000
- Gross proceeds
- $150.00M
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Feb 3, 2027
“The initial public offering price is $16.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 7, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 4, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?